Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/ β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, ...

Source: Respiratory Research - September 9, 2020 Category: Respiratory Medicine Authors: Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika W ählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal and Ioannis Psallidas Tags: Research Source Type: research